Clinical Trial Update: Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders. [Phase 1]

View source ↗

Summary

A pediatric pharmacokinetic study of Glivec/Gleevec (imatinib) in children aged 1 to less than 4 with chronic myeloid leukemia, Philadelphia chromosome–positive…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Eosinophilic Leukemia
• Hypereosinophilic Syndrome
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• Glivec/Gleevec (imatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) | Phase 1 | Status: TERMINATED